Clinical Factors Associated with Acquisition of Resistance to Levofloxacin in Stenotrophomonas maltophilia

키워드

참고문헌 (34)

1. Garazi M, "Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review", J Hosp Infect, 81, pp.114~118 (2012)
2. Brooke JS, "Stenotrophomonas maltophilia: an emerging global opportunistic pathogen", Clin Microbiol Rev, 25, pp.2~41 (2012)
3. Fihman V, "Stenotrophomonas maltophilia--the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study", J Infect, 64, pp.391~398 (2012)
4. Araoka H, "Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy", Transpl Infect Dis, 14, pp.355~363 (2012)
5. Falagas ME, "Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature", Future Microbiol, 4, pp.1103~1109 (2009)
6. Sanchez MB, "Stenotrophomonas maltophilia drug resistance", Future Microbiol, 4, pp.655~660 (2009)
7. Abbott IJ, "Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment", Expert Rev Anti Infect Ther, 9, pp.471~488 (2011)
8. Toleman MA, "Global emergence of trimethoprim", sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes, 2007, pp.13, 559~565
9. Chang LL, "Increased incidence of class 1 integrons in trimethoprim", sulfamethoxazole-resistant clinical isolates of Stenotrophomonas maltophilia, 2007, pp.59, 1038~1039
10. Gales AC, "Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999)", Clin Infect Dis, 32(Suppl 2), pp.S104~S113 (2001)
11. Sader HS, "Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli", Int J Antimicrob Agents, 25, pp.95~109 (2005)
12. Farrell DJ, "Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections", Antimicrob Agents Chemother, 54, pp.2735~2737 (2010)
13. Nicodemo AC, "Antimicrobial therapy for Stenotrophomonas maltophilia infections", Eur J Clin Microbiol Infect Dis, 26, pp.229~237 (2007)
14. Korakianitis I, "Post-antibiotic effect (PAE) of moxifloxacin in multidrug-resistant Stenotrophomonas maltophilia", Int J Antimicrob Agents, 36, pp.387~389 (2010)
15. Weiss K, "Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia", J Antimicrob Chemother, 45, pp.363~365 (2000)
16. Valdezate S, "Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains", Antimicrob Agents Chemother, 45, pp.1581~1584 (2001)
17. Garrison MW, "Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model", Antimicrob Agents Chemother, 40, pp.2859~2864 (1996)
18. CLSI, "Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement" (2011), Clinical and Laboratory Standard Institute
19. Hernández A, "Structural and functional analysis of SmeT, the repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF", J Biol Chem, 284, pp.14428~14438 (2009)
20. Zhang L, "Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system", Antimicrob Agents Chemother, 44, pp.287~293 (2000)
21. Gordon NC, "Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia", J Antimicrob Chemother, 65, pp.483~489 (2010)
22. Cheng AF, "Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy", J Antimicrob Chemother, 20, pp.283~285 (1987)
23. Ansari SR, "Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer", Cancer, 109, pp.2615~2622 (2007)
24. Spanik S, "Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study", J Infect Chemother, 5, pp.180~184 (1999)
25. Rodríguez-Martínez JM, "Plasmid-mediated quinolone resistance: an update", J Infect Chemother, 17, pp.149~182 (2011)
26. Araoka H, "Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996-2009", Eur J Clin Microbiol Infect Dis, 29, pp.605~608 (2010)
27. Gülmez D, "Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital", Clin Microbiol Infect, 11, pp.880~886 (2005)
28. Lai CH, "Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia", J Microbiol Immunol Infect, 37, pp.350~358 (2004)
29. Tseng CC, "Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia", Infect Control Hosp Epidemiol, 30, pp.1193~1202 (2009)
30. Alonso A, "Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance", Antimicrob Agents Chemother, 44, pp.1778~1782 (2000)
31. Sánchez MB, "SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia", Antimicrob Agents Chemother, 54, pp.580~581 (2010)
32. Sánchez MB, "Differential epigenetic compatibility of qnr antibiotic resistance determinants with the chromosome of Escherichia coli", PLoS One, 7, pp.e35149~ (2012)
33. 정혜영, "Heterogeneous Spectrum of CFTR Gene Mutations in Korean Patients with Cystic Fibrosis", Annals of Laboratory Medicine, 31(3), pp.219~224 (2011), 대한진단검사의학회
34. Nicodemo AC, "In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods", J Antimicrob Chemother, 53, pp.604~608 (2004)

관련 논문AI추천